 |
Baxter Oncology has been established worldwide
with standard therapy products for cancer, such as ENDOXAN
(cyclophosphamide), HOLOXAN
(ifosfamide), and UROMITEXAN
(mesna), for over 40 years. This product range has been steadily
expanded to include MILTEX (miltefosine), ONKOTRONE
(mitoxantrone), BLEOMYCIN (Bleomycin) and others, some only available regionally.
The long-term objective is to help improve the treatment of cancer patients worldwide through the development, production, marketing, and sale of new, improved products in close cooperation with physicians, pharmacists, other care personnel, renowned scientists, organizations and associations, and with committed partner companies.
|
|
|
